Navigation Links
Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Date:12/19/2007

ease that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the effect of the completion of the Phase 2 clinical trial for Amigal for the treatment of Fabry disease, the plans for the Phase 3 clinical trial for Amigal, the Phase II clinical trials for Plicera(TM) for the treatment of Gaucher disease, and the effect of the completion of the Phase I clinical trials for AT2220 for the treatment of Pompe disease may not proceed in the timeframes or in the manner Amicus expects or at all. Further, the results of earlier clinical trials may not be predictive of future results; Amicus and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks detailed in the public filings of Amicus with the Securities and Exchange Commission. You are cauti
'/>"/>
SOURCE Amicus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 The Pittcon Organizing Committee ... Food Safety Tech , an e-Journal and producer of ... agreement for the second year for the co-location of Food ... The partnership provides that the registration fee to attend the ...
(Date:1/15/2014)... January 15, 2014 Look inside the ... items for the lab, from fluid handling to instruments ... to ship when you order. , Preferred Solutions ... , from the L/S® model for precise flow control ...
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... conjugates for cancer, today announced the appointment of Thomas C ... has over 20 years, development experience gained in the biotechnology ... "I am delighted to welcome Tom at this ...
(Date:1/15/2014)... 15, 2014 This webinar will focus ... clinical safety assessment in biosimilars. , Regulatory frameworks are ... drug development, however the complex nature of biopharmaceuticals makes ... and efficacy extremely challenging. Based on the specific aspects ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... Inc. (Amex: ADL ), today announced the promotion ... (COO) and CFO. The Company is also,expanding its management ... of International Marketing and Sales and Mr. Raymond Gatchalian ... and CFO, Mr. Ariura will lead the day-to-day operations ...
... SNDY) is pleased to announce that the Company has ... St. Mary,s,Hospital in Waterbury, CT. St. Mary,s has been ... it has chosen to continue using the,Company,s surgical products., ... in the history of Greater,Waterbury, providing nearly a century ...
... CHICAGO, Nov. 6 Advanced Life Sciences,Holdings, Inc. ... in the,discovery, development and commercialization of novel drugs ... diseases, today,announced its financial results for the third ... ), The net loss available to common ...
Cached Biology Technology:AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team 2AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team 3AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team 4Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital 2Advanced Life Sciences Announces Third Quarter 2008 Financial Results 2Advanced Life Sciences Announces Third Quarter 2008 Financial Results 3Advanced Life Sciences Announces Third Quarter 2008 Financial Results 4Advanced Life Sciences Announces Third Quarter 2008 Financial Results 5Advanced Life Sciences Announces Third Quarter 2008 Financial Results 6Advanced Life Sciences Announces Third Quarter 2008 Financial Results 7Advanced Life Sciences Announces Third Quarter 2008 Financial Results 8Advanced Life Sciences Announces Third Quarter 2008 Financial Results 9Advanced Life Sciences Announces Third Quarter 2008 Financial Results 10Advanced Life Sciences Announces Third Quarter 2008 Financial Results 11
(Date:4/17/2014)... deforestation and fragmentation of forests in the Amazon ... forests, contributing to rapid and widespread forest loss ... researchers., The findings show that forests in the ... droughts coupled with forest fires lead to large-scale ... Jennifer Balch, assistant professor of geography, Penn State. ...
(Date:4/17/2014)... new early-warning signs of the potential loss of sight ... for the diagnosis and treatment of diabetic retinopathy, potentially ... "We had not expected to see such striking changes ... Elsner, professor and associate dean in the IU School ... set out to study the early signs, in volunteer ...
(Date:4/17/2014)... the Australian National University (ANU), have developed a ... temperature variability over the past 5.3 million years., ... climate surrounding ice ages over the past two ... between carbon dioxide levels, global temperatures and sea ... Southampton (UoS) and the National Oceanography Centre (NOC) ...
Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Ancient sea-levels give new clues on ice ages 2
... new eco-friendly way of dissolving wood using ionic liquids ... as bio fuels, textiles, clothes and paper. Dr ... School of Chemistry and Chemical Engineering worked along with ... with a more cost and energy efficient way of ...
... recent rapid growth of institutional Memberships for open ... introduction of the "Online Reporting System" for its ... on BioMed Central,s cutting edge publishing platform, the ... budgeting and help reduce the administrative costs associated ...
... presentation, “New Strategies for Optimizing CHO Performance,” to ... called ZAP-CHO during BIO 2009 International Convention in ... 2009 / b3c newswire / – InVitria’s ... present the performance enhancing features of ZAP-CHO, a ...
Cached Biology News:Queen's scientists discover eco-friendly wood dissolution 2InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO 2
... compatible with ABI thermal cyclers, QPCR instruments ... characteristics can be sealed with heat ... Certified free of DNase, RNase and human ... Fisher Scientific, the world leader in serving ...
AVOID FREEZE/THAW CYCLES. Recognizes the ~32 kDa DNase IIα chain and the ~40 kDa proenzyme. DNase II causes both DNA condensation and DNA fragmentation. ...
BD BioCoat Vented Caps for 175 cm2 Flasks...
...
Biology Products: